SandboxAQ and MapLight Therapeutics have entered into a strategic collaboration to discover and develop potential first-in-class treatments targeting a novel G protein-coupled receptor (GPCR) linked to central nervous system (CNS) disorders.
What the Collaboration Covers?
Under the agreement, SandboxAQ will receive an upfront payment and is eligible for up to $200 million in preclinical, development, regulatory, and commercial milestone payments. Both companies will jointly conduct preclinical research, while MapLight Therapeutics retains exclusive rights to advance successful compounds into clinical development and commercialization.
AI-Driven Drug Discovery at the Core
The partnership brings together SandboxAQ’s advanced AI and molecular simulation platform (AQBioSim) with MapLight’s deep expertise in CNS biology. SandboxAQ will use large-scale AI models and high-fidelity simulations to:
- Explore GPCR structure–function relationships
- Predict ligand–receptor interactions
- Optimize drug-like properties
- Accelerate Design–Make–Test–Analyze (DMTA) cycles
This approach is designed to rapidly narrow down promising candidates in chemical space that traditional methods often struggle to access.
Why This Matters for CNS Drug Development?
GPCRs remain one of the most important but challenging target classes in drug discovery, especially in CNS diseases where unmet need remains high. By combining AI-driven simulations with biological validation, the collaboration aims to unlock previously hard-to-drug GPCR targets and generate differentiated, first-in-class therapies.
What the Companies Are Saying?
MapLight Therapeutics highlighted that the novel target was identified and validated using its internal discovery platform, while SandboxAQ emphasized that its technology enables a level of precision in GPCR modeling that was not previously possible.
Together, the companies aim to accelerate the discovery of innovative CNS treatments that could address significant gaps in current care.
About the Partners
- SandboxAQ is a B2B company operating at the intersection of AI and quantum-inspired technologies, delivering large quantitative models across life sciences and other industries.
- MapLight Therapeutics is focused on developing novel therapies for central nervous system disorders by targeting innovative biological mechanisms.
This collaboration underscores the growing role of AI-led platforms in reshaping early-stage drug discovery, particularly for complex targets in neurology and psychiatry.
